The increased regulation of intellectual property rights for pharmaceutical brand owners across the globe poses a number of jurisdiction-specific challenges. As the concept of tobacco plain packaging becomes enshrined in regulation, the implications on the pharmaceutical industry are increasingly brought to the forefront of discussion.
This publication considers the interaction between local intellectual property laws and regulatory frameworks surrounding the naming, packaging, labelling and advertising of pharmaceutical products in:
- Australia
- EU and UK
- China
- The United States
- Canada
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.